Sophia Genetics Sa (SOPH)

Nasdaq: SOPH · Services-Computer Processing & Data Preparation · Rolle, CH · filing with the SEC since 2021

Full chart Alerts Compare

Grade4.6

◀ Past 6.1● Present 3.1▶ Future 5.0

2 est.

Overview Business Financials Grade Forecast Sentiment Ownership People Filings Patents Chart

The grade of Sophia Genetics Sa

Nine metrics read from its own filings, by tense

Headline grade

4.6/10

◀ Past6.130% of the headline

● Present3.140% of the headline

▶ Future5.030% of the headline

All three tenses have at least two readings, so the archetype blend applies as printed.

Of the nine metrics, 7 read as filed from the record and 2 are SI estimates, each with its reasoning, its confidence and what would change it on its card.

◀ Past

What did they actually do?

6.1/1030% of the headline grade · 2 of 3 filed, 1 estimated

Surviving crises

as filed

7.5/10

Has it survived what it has been through?

No warning events in its filings since 2021.

weight 33% of this tense · 75th percentile among 77 sector filers · read for itself

From the record

Sophia Genetics Sa's filings since 2021 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Track record

as filed

5.8/10

What has it actually done, year after year?

+20.4% a year over 7 filed years; profitable in 0 of 7.

weight 45% of this tense · 58th percentile among 64 sector filers · read for its customers

From the record

Sophia Genetics Sa's 7 filed years say what it did: revenue went from $25 million in fiscal 2019 to $77 million in fiscal 2025, up 20.4% a year; it rose in 6 of 6 years; it never fell from a peak; net income was positive in 0 of 7 of those years (its annual reports).

What it rests on

revenue growth over the filed span20.4%top 36% of its family
the share of years revenue rosetop 21% of its family
the share of filed years with a profitbottom 12% of its family
the deepest fall from a revenue peak0.0%top 21% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Shareholder treatment

SI estimate

4.7/10

How has it treated the people who own it?

SI estimate 4.7/10, confidence 35 of 100 (one part).

weight 22% of this tense · 47th percentile among 69 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate: Read from one part only, the share count over the years, which ranks in the bottom 47% of 69 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
What the record cannot read: Fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
How it was reasoned: one part: the share count over the years, the one part on file, ranked among 69 in its family.
Confidence: 35 of 100
What would change it: A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Sophia Genetics Sa's shareholder treatment is put at 4.7 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the bottom 47% of 69 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.

● Present

What are they doing right now?

3.1/1040% of the headline grade · 2 of 3 filed, 1 estimated

Financial health

as filed

3.4/10

Is it financially healthy right now?

ROE -168%: lost 168¢ per shareholder dollar. Leverage 71%: owes 71¢ per asset dollar.

weight 33% of this tense · 34th percentile among 69 sector filers · read for itself

From the record

Return on equity: in the fiscal year ended 2025-12-31, Sophia Genetics Sa lost about 168 cents for every dollar of shareholders' money, and gross profitability: its products earned about 32 cents per dollar of everything the company owns. Leverage: it owed about 71 cents per dollar of assets, and net share issuance: its share count grew 2.2% over the year (the filed statements).

What it rests on

what it owes per dollar of assetsbottom 31% of its family
return on equitybottom 6% of its family
gross profit against assetsbottom 49% of its family
the share count against the year beforetop 49% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Industry position

as filed

4.0/10

How strong is its position in its industry?

bottom 40% of 68 in its family; net margin -102.2%.

weight 45% of this tense · 40th percentile among 68 sector filers · read for its customers

From the record

Sophia Genetics Sa's standing among 68 graded names in its industry family: revenue of $77 million in fiscal 2025 ranks in the bottom 28% by size; a net margin of -102.2% ranks in the bottom 15%; revenue growth of 17.6% a year over the last 3 filed years ranks in the top 22% (its annual reports).

What it rests on

revenue against the family$77.3Mbottom 28% of its family
net margin-102.2%bottom 15% of its family
three-year revenue growth17.6%top 22% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Leadership

SI estimate

0.7/10

What are the people in charge doing?

SI estimate 0.7/10, confidence 35 of 100 (one part).

weight 22% of this tense · 7th percentile among 55 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate: Read from one part only, the chief executive's years under the title, which ranks in the bottom 7% of 55 in its family; it files no Form 8-K (a foreign issuer reports on Form 6-K), so officer and director changes cannot be read there; the record of its people begins on 2026-03-18 (a listing, a merger or a first filing under the rules) and most of the people in charge have filed since then, so the record shows a floor of 8 months and cannot see past it; a floor under five years is not read as years in charge.
What the record cannot read: It files no Form 8-K (a foreign issuer reports on Form 6-K), so officer and director changes cannot be read there; the record of its people begins on 2026-03-18 (a listing, a merger or a first filing under the rules) and most of the people in charge have filed since then, so the record shows a floor of 8 months and cannot see past it; a floor under five years is not read as years in charge.
How it was reasoned: one part: the chief executive's years on the record, the one part on file, ranked among 55 in its family.
Confidence: 35 of 100
What would change it: A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Sophia Genetics Sa's leadership is put at 0.7 of 10 with a confidence of 35 of 100, because read from one part only, the chief executive's years under the title, which ranks in the bottom 7% of 55 in its family; it files no Form 8-K (a foreign issuer reports on Form 6-K), so officer and director changes cannot be read there; the record of its people begins on 2026-03-18 (a listing, a merger or a first filing under the rules) and most of the people in charge have filed since then, so the record shows a floor of 8 months and cannot see past it; a floor under five years is not read as years in charge. A filing that carries the missing parts replaces this estimate with the filed reading.

▶ Future

What are they set up to do next?

5.0/1030% of the headline grade · 3 of 3 filed

Room to expand

as filed

6.1/10

How much room does it have to grow?

top 39% of 68 in its family for room to expand.

weight 22% of this tense · 61st percentile among 68 sector filers · read for itself

From the record

Sophia Genetics Sa's room to grow, from the newest filed statements (fiscal 2025): cash of $70 million against no long-term debt tagged leaves 43.1% of its assets as net cash, top 24% of its family; cash from operations less capital spending is -47.2% of revenue (bottom 26%); a gross margin of 67.4% (top 44%); research spending of 44.3% of revenue (top 15%) (its annual report).

What it rests on

cash less debt against assets43.1%top 24% of its family
cash from operations less capital spending against revenue-47.2%bottom 26% of its family
gross margin67.4%top 44% of its family
research spending against revenue44.3%top 15% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Growth drivers

as filed

4.5/10

What could actually drive growth from here?

bottom 44% of 64 in its family for growth drivers.

weight 45% of this tense · 44th percentile among 64 sector filers · read for its customers

From the record

Sophia Genetics Sa's growth drivers, from the filed years to fiscal 2025: revenue grew 17.6% a year over the last three filed years against 20.4% over all 7, slowing (bottom 46% of its family); the newest year grew 18.6% (top 31%); research spending grew -1.1% a year (top 49%); capital spending grew -48.1% a year (bottom 12%) (its annual reports). Sophia Genetics Sa tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

What it rests on

three-year growth against the whole span-2.8 points a yearbottom 46% of its family
the newest year's revenue growth18.6%top 31% of its family
three-year growth of research spending-1.1%top 49% of its family
three-year growth of capital spending-48.1%bottom 12% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Expectations vs reality

as filed

4.9/10

Did its newest year beat what its own record pointed to?

bottom 49% of 54 in its family for expectations against reality.

weight 33% of this tense · 49th percentile among 54 sector filers · read for its shareholders

From the record

Sophia Genetics Sa's newest year against its own record: revenue of $77 million in fiscal 2025 came in 1.3% above the $76 million its prior three years' pace pointed to (bottom 45% of its family); net income of $79 million against a prior three-year average of $76 million (bottom 28%); a net margin of a loss larger than its revenue against losses larger than its revenue before (top 25%) (its annual reports).

What it rests on

revenue against the prior three years' pace1.3%bottom 45% of its family
net income against the prior three years' average-4%bottom 28% of its family
net margin against its prior average+33.2 pointstop 25% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made

SI Assistanton SOPH · research, not advice